Case studies on RetroMAD1™, an orally administered recombinant chimeric protein to treat naturally infected FelineLeukemia Virus (FeLV) cats. Archives of Veterinary Science and Medicine 2 (2019): 041-057. Abstract Treatment options for Feline leukimia are presently very limited due to lack of efficacy and drug toxicity. A recombinant chimeric protein RetroMAD1 is described for the first time in the treatment of FeLV. The chimera has an A-B-C configuration comprising of multiple documented antiviral domains that can potentially overcome single point mutation driven resistance by multidomain action. Oral administration of RetroMAD1 was given daily at 0.4mg/kg/day divided equally into two feeds roughly 12 hours apart for one month to highly symptomatic FeLV cats in Brazil. RetroMAD1 treated cats were monitored for survival until day 433 and untreated cats were monitored until day 173. A significant different in survival rate of 73% (treated N=55) versus 33% (untreated N=21) existed. Gingivitis, F.U.R.D. and anaemia were shown to improve significantly as signs indicating improvement in quality of life. Some of the RetroMAD1 treated cats were given interferon treatment by their respective vets as supportive treatment (N=14) that gave a slightly improved survival outcome compared to those given only RetroMAD1 and other supportive medication.
Introduction
Feline Leukimia (FeLV) is responsible for more illness in cats globally than any other virus [1] . Three subgroups exist as FeLV-A being the most common, that contain an RNA glycosidase domain [17] . It cleaves the terminal adenine of the α-SRL (sarcin-ricin loop) of the ribosomal large subunit that affects interaction between the elongation factor and the ribosome. MAP30 has a broad-spectrum antiviral activity that suggests that inhibiting the elongation factor causes host ribosomes inactivation in virally infected cells [18] . Recombinant MAP30 has been shown to be capable of relaxing HIV1 supercoiled DNA and catalyzing double-strand breakage to form topologically inactive products [19] .
Dermaseptins are cationic antimicrobial peptides (CAP) from tree frogs that play a key defensive role against enveloped viruses including HIV1, HSV and HPV whose ability to destabilize membranes due to their amphiphilic are thought to contribute to block viral entry [20] . Dermaseptin S4 has been demonstrated to inhibit HIV1 infectivity against human primary Tlymphocytes by affecting virion integrity [21] .
By targeting different viral entry steps, bAVPs (bifunctional antiviral proteins) inhibit viral entry better [22] . Both tenofovir and raltegravir have anti-HIV-1 mechanisms thought to be similar for FeLV being chain elongation inhibition at the ribosomal level (for tenofovir) and integration inhibition (for raltegravir) both of which have been described for MAP30 not to mention relaxation of supercoiled DNA giving rise to double-strand breakage [17] [18] [19] . Coupled with retrocyclin being a glycoprotein blocking entry inhibitor the stage is set for RetroMAD1 to being a potentially multifunctional antiviral chimeric protein [15] , [16] .
Additionally, a team from Cambridge University has shown using a VLP (viral like particle) model containing fluorescent dye fusing with liposomes that Written owner consent for blood collection and for the use of blood samples and all data for scientific purposes is routinely given at the admission examination each time a patient visits the clinic during routine visits prior to blood donation. Therefore, based on the regulations, formal ethical approval for this study was not needed.
Treatment Regime
Oral daily administration of RetroMAD1 given at 0.4mg/kg/day (divided equally into two feeds roughly 12 hours apart). RetroMAD1 is an almost colourless liquid without negative taste response in cats.
RetroMAD1 was contained in clear autoclaved sterile borosilicate glass bottles of 50 ml. Each owner was instructed to store RetroMAD1 at 4°C and equilibrate to ambient temperature (20-30°C) prior to dispensing using plastic droppers.
Clinical Scoring and Complete Blood Count (CBC)
Criteria selected for clinical scoring as tabulated in Table 1 were agreed by consensus among some 
RetroMAD1 Description
RetroMAD1 is a clear slightly yellowish odourless fully miscible liquid at pH 11 containing the target protein around 37-40 kDa. Stability at tropical room temperature (26-34°C) is >99% viral reduction of HSV2 on vero cell (ATCC CC-81) over 4 years. The Batch used for this trial was #51 where QC gave an MNTD of 100-120 µg/ml and an antiviral concentration of 100 µg/ml with a 4-log reduction of virus using RT-PCR.
Malaysian RT-PCR Dataset
After the Brazilian trial, 6 highly symptomatic 
Statistical Analysis
Data analysed using GraphPad Prism version 5.02 for Windows (GraphPad Software Inc., La Jolla, CA, USA). Survival curves for cats were estimated by the . Some cats in this study were also interferon/RetroMAD1 treated as some vets used this as supportive therapy. This provides insight on possible synergism discussed later. Haematocrit increased slightly by 2% with a probability value of P = 0.0534 that was just approaching the limit of significance at P ≤ 0.05. Both values are within the reference range. All other parameters were also not statistically different before and after treatment and were within the given reference range. Only the MCH paired dataset of N=10 was much less than the others due to the fact that only one lab carried out this particular analysis.
Vet Scores

PCR result
Six symptomatic progressive FeLV cats in Kuala
Lumpur, Malaysia were treated with RetroMAD1 to retrospectively study its effect on viral titre. Table 7 showed that viral copy number reduction ranged from a low of 53% to a high of 100% (undetectable by RT-PCR). A plasma viremia loads greater than 1 x 10 3 copies per ml is considered high [3] . Although this is a preliminary uncontrolled study, a 1-3 log reduction was 
Conclusion
